DK1140181T3 - Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi - Google Patents

Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi

Info

Publication number
DK1140181T3
DK1140181T3 DK99968939T DK99968939T DK1140181T3 DK 1140181 T3 DK1140181 T3 DK 1140181T3 DK 99968939 T DK99968939 T DK 99968939T DK 99968939 T DK99968939 T DK 99968939T DK 1140181 T3 DK1140181 T3 DK 1140181T3
Authority
DK
Denmark
Prior art keywords
inhibitor
radiation therapy
neoplasia
cox
treatment
Prior art date
Application number
DK99968939T
Other languages
English (en)
Inventor
Jaime L Masferrer
Luka Milas
John P Mckearn
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of DK1140181T3 publication Critical patent/DK1140181T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
DK99968939T 1998-12-23 1999-12-22 Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi DK1140181T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11378698P 1998-12-23 1998-12-23
US09/385,214 US6649645B1 (en) 1998-12-23 1999-08-27 Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EP99968939A EP1140181B1 (en) 1998-12-23 1999-12-22 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia

Publications (1)

Publication Number Publication Date
DK1140181T3 true DK1140181T3 (da) 2005-02-14

Family

ID=26811473

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968939T DK1140181T3 (da) 1998-12-23 1999-12-22 Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi

Country Status (19)

Country Link
US (3) US6649645B1 (da)
EP (2) EP1140181B1 (da)
JP (1) JP2002535249A (da)
KR (1) KR100705744B1 (da)
AT (1) ATE281845T1 (da)
AU (1) AU769665B2 (da)
BR (1) BR9916544A (da)
CA (1) CA2356547A1 (da)
CY (1) CY1105584T1 (da)
DE (1) DE69921852T2 (da)
DK (1) DK1140181T3 (da)
EA (1) EA200100571A1 (da)
ES (1) ES2232205T3 (da)
HU (1) HUP0104669A3 (da)
IL (2) IL143805A0 (da)
NO (1) NO20013064L (da)
PL (1) PL349149A1 (da)
PT (1) PT1140181E (da)
WO (1) WO2000038716A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MXPA02012879A (es) * 2000-06-20 2004-07-30 Herbst Arthur L Inhibidores de ciclooxigenasa-2 y la prevencion de los efectos secundarios de terapia por radiacion.
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
FR2820636B1 (fr) * 2001-02-09 2007-10-05 Laprophan Laboratoires De Prod Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
AU2003217697A1 (en) * 2002-02-25 2003-09-09 University Of Rochester Medical Center Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity
OA12977A (en) 2002-12-19 2006-10-13 Pfizer 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthamic diseases.
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US20080199484A1 (en) * 2003-10-06 2008-08-21 Cedars-Sinai Medical Center Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
ES2341351T3 (es) 2004-08-26 2010-06-18 Pfizer, Inc. Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas.
WO2006040676A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors
JP5197355B2 (ja) * 2005-03-08 2013-05-15 三井農林株式会社 ポリフェノールとコキシブの組み合わせおよび方法
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
EP2205075A4 (en) * 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc THERAPIES FOR THE TREATMENT OF CANCER BASED ON COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND OSTROGEN RECEPTOR ANTAGONISTS
CA2707153A1 (en) * 2007-11-28 2009-06-04 Tragara Pharmaceuticals, Inc. Cancer treatment using cox-2 inhibitor and antimetabolite combinations
US20110086850A1 (en) * 2008-04-11 2011-04-14 Board Of Regents, The University Of Texas System Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8002838B2 (en) * 2008-06-11 2011-08-23 Depuy Products, Inc. Joint prosthesis with positionable head
PT3150610T (pt) 2010-02-12 2019-11-11 Pfizer Sais e polrmorfos de 8-fluor0-2-{4- [(metilamino}metil]fenil}-1,3,4,5-tetrahidr0-6hazepin0[ 5,4,3-cd]indol-6-0na
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US5663180A (en) 1983-10-29 1997-09-02 G.D. Searle & Co. Substituted cyclopentenes for the treatment of inflammation
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
JPH0766587B2 (ja) 1990-10-20 1995-07-19 エルジー電子株式会社 Ｖｃｒの予約録画方法
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
AU5292193A (en) * 1992-10-02 1994-04-26 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
EP0595546B1 (en) 1992-10-28 1996-03-20 Shionogi & Co., Ltd. Benzylidene derivatives
WO1994012169A1 (en) * 1992-11-25 1994-06-09 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CA2297592A1 (en) 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US6274590B1 (en) 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
KR100229343B1 (ko) 1993-11-30 1999-11-01 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
WO1996003392A1 (en) 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5696143A (en) 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
GB2294879A (en) 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
WO1996013483A1 (en) 1994-10-27 1996-05-09 Merck Frosst Canada Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5908852A (en) 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU699593B2 (en) 1995-02-13 1998-12-10 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
EP1288206B1 (en) 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
KR100205229B1 (ko) 1996-05-15 1999-07-01 윤종용 태양전지 전원장치
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5863946A (en) 1996-06-06 1999-01-26 Abbott Laboratories Iminoxyderivatives of fenamates as inhibitors of prostaglandin biosynthesis
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
IL154501A0 (en) * 1996-10-15 2003-09-17 Searle & Co Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
JPH10158234A (ja) * 1996-12-02 1998-06-16 Kotobuki Seiyaku Kk ２−フェニルアズレン誘導体及びその製造方法
ES2208964T3 (es) 1996-12-10 2004-06-16 G.D. SEARLE & CO. Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
ATA16597A (de) * 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
FR2769311B1 (fr) 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6277878B1 (en) 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
IL143805A (en) 2007-03-08
NO20013064L (no) 2001-08-23
ATE281845T1 (de) 2004-11-15
AU2713400A (en) 2000-07-31
PT1140181E (pt) 2005-02-28
KR100705744B1 (ko) 2007-04-11
EP1522313A1 (en) 2005-04-13
US6649645B1 (en) 2003-11-18
ES2232205T3 (es) 2005-05-16
US20040053935A1 (en) 2004-03-18
BR9916544A (pt) 2002-01-08
NO20013064D0 (no) 2001-06-20
HUP0104669A3 (en) 2002-08-28
EP1140181A1 (en) 2001-10-10
DE69921852D1 (de) 2004-12-16
IL143805A0 (en) 2002-04-21
AU769665B2 (en) 2004-01-29
DE69921852T2 (de) 2005-10-27
KR20010109273A (ko) 2001-12-08
US20040053934A1 (en) 2004-03-18
CY1105584T1 (el) 2010-07-28
EP1140181B1 (en) 2004-11-10
JP2002535249A (ja) 2002-10-22
PL349149A1 (en) 2002-07-01
CA2356547A1 (en) 2000-07-06
WO2000038716A1 (en) 2000-07-06
EA200100571A1 (ru) 2001-12-24
WO2000038716A9 (en) 2000-11-30
HUP0104669A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
DK1140181T3 (da) Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
DK0830864T3 (da) Kombinationsbehandling til behandling af psykoser
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0927555T3 (da) Anvendelse af cyclooxygenase-2-hæmmere til behandling og forebyggelse af tumorer, tumorrelaterede forstyrrelser og kakesi
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
IS6576A (is) Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
NO20010390L (no) Behandling av angstsykdommer
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту